Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning
Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adu...
Saved in:
| Published in | European journal of haematology Vol. 88; no. 1; pp. 46 - 51 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.01.2012
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0902-4441 1600-0609 1600-0609 |
| DOI | 10.1111/j.1600-0609.2011.01724.x |
Cover
| Abstract | Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC (P < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation (P = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis (P < 0.01), and previous SBI before day +30 (P < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions: After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF. |
|---|---|
| AbstractList | Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period ( Background and objectives : Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods : The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results : FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC ( P < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation ( P = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 ( P < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis ( P < 0.01), and previous SBI before day +30 ( P < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions : After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF. Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo). The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. After an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF. Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100 d post‐transplant in 195 consecutive adult recipients of a reduced‐intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC‐allo). Materials and methods: The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia. Results: FN occurred in 141 patients (72%), always in the first 30 d post‐allo‐RIC. However, a SBI occurred in only 27 patients (14%) during this early post‐transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post‐transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo‐RIC (P < 0.02) and NCI CTC grade III–IV mucosal damage in the first 10 d post‐transplantation (P = 0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P < 0.01), mycophenolate mofetil‐based graft‐versus‐host disease (GVHD) prophylaxis (P < 0.01), and previous SBI before day +30 (P < 0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs. Conclusions: After an RIC‐allo, FN and early SBI occurred mostly in patients with severe mucositis and early‐onset neutropenia, while postengraftment high‐dose steroid therapy for acute GVHD was the major RF. Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo).BACKGROUND AND OBJECTIVESWhether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed the risk factors (RFs) for the development of FN and SBI in the first 100d post-transplant in 195 consecutive adult recipients of a reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-allo).The RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia.MATERIALS AND METHODSThe RIC regimens consisted of fludarabine plus melphalan (62%) or busulphan (38%) (FluMel or FluBu). SBIs include pneumonia, urinary tract infections, and bacteremia.FN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs.RESULTSFN occurred in 141 patients (72%), always in the first 30d post-allo-RIC. However, a SBI occurred in only 27 patients (14%) during this early post-transplant period (<day +30), while 29 evaluable patients (15%) developed a SBI in the intermediate post-transplant period (days +31 to +100). In multivariate analysis, RFs for the development of FN included onset of neutropenia before day +5 after allo-RIC (P<0.02) and NCI CTC grade III-IV mucosal damage in the first 10d post-transplantation (P=0.03). RFs identified to SBI by multivariate analysis included corticosteroid therapy before day +100 (P<0.01), mycophenolate mofetil-based graft-versus-host disease (GVHD) prophylaxis (P<0.01), and previous SBI before day +30 (P<0.01). The rate of SBI from day +30 to +100 varied according to the number of RFs; thus, the rate of SBI was 1% in patients without any RF, 17% in patients with one RF, 29% with one RFs, and 53% in those with all three RFs.After an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF.CONCLUSIONSAfter an RIC-allo, FN and early SBI occurred mostly in patients with severe mucositis and early-onset neutropenia, while postengraftment high-dose steroid therapy for acute GVHD was the major RF. |
| Author | Facchini, Luca Valcárcel, David Sierra, Jorge Granell, Miguel Briones, Javier Martino, Rodrigo Delgado, Julio Ferrari, Angela Sureda, Anna Brunet, Salut Piñana, José L. Barba, Pere |
| Author_xml | – sequence: 1 givenname: Luca surname: Facchini fullname: Facchini, Luca organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 2 givenname: Rodrigo surname: Martino fullname: Martino, Rodrigo organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 3 givenname: Angela surname: Ferrari fullname: Ferrari, Angela organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 4 givenname: José L. surname: Piñana fullname: Piñana, José L. organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 5 givenname: David surname: Valcárcel fullname: Valcárcel, David organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 6 givenname: Pere surname: Barba fullname: Barba, Pere organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 7 givenname: Miguel surname: Granell fullname: Granell, Miguel organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 8 givenname: Julio surname: Delgado fullname: Delgado, Julio organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 9 givenname: Javier surname: Briones fullname: Briones, Javier organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 10 givenname: Anna surname: Sureda fullname: Sureda, Anna organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 11 givenname: Salut surname: Brunet fullname: Brunet, Salut organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain – sequence: 12 givenname: Jorge surname: Sierra fullname: Sierra, Jorge organization: Hematology Department of the Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22023368$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1v1DAQjVAR3Rb-AvINLtmOnQ8nB5BQvxZUAUJFPVqOMy7eZu3FdmD3x_Hf6nTbSnBA9cWjmffejP3mINuzzmKWEQpzms7Rck5rgBxqaOcMKJ0D5aycb55ls8fCXjaDFlheliXdzw5CWAIAayl_ke0zBqwo6maW_TnBa49InCarUblgoglE2p70o5fRODtVLI7RuzVaI4n0SOIPJCu5dJ54E26Ilio6H4hOCZR-2JK1CzGPXtqwHqSNRGPnzYB_C6UmAX9h0uuSAHojB2KsRjW1TUPolCMe-1Fhnxsb0abptkQ525sJYuz1y-y5lkPAV_f3Yfb97PTyeJFffDn_ePzhIlcVVGWOXLelho6XXFJdd2XHW15j0XSFhKpoecUpS2Ffs0KpRsmKS0DZVaAa6GldHGZvdrpr736OGKJYmaBwSI9DNwbRUtqWVQUT8u1_kRQYNCVwzhL09T107FbYi7U3K-m34sGcBHi_AyjvQvCohTLxzpT0tWZIWmLaBrEUk-liMl1M2yDutkFskkDzj8BDjydQ3-2ov5Nv2yfzxOmnxRQlfr7jmxBx88iX_kbUvOCVuPp8Lr6eXF7xb4szAcUty_rffQ |
| CitedBy_id | crossref_primary_10_1007_s00280_020_04118_9 crossref_primary_10_6014_jjsom_19_35 crossref_primary_10_1093_jncimonographs_lgz002 crossref_primary_10_1111_odi_14999 crossref_primary_10_1016_j_ejon_2017_11_006 crossref_primary_10_7889_hct_4_23 crossref_primary_10_4236_aid_2014_42013 crossref_primary_10_1016_j_medcli_2017_09_005 crossref_primary_10_7889_hct_18_013 crossref_primary_10_1007_s00520_024_08776_w crossref_primary_10_1007_s00520_021_06177_x crossref_primary_10_1016_j_ccm_2024_10_010 crossref_primary_10_1182_bloodadvances_2019000226 crossref_primary_10_1007_s00520_015_2848_9 crossref_primary_10_3201_eid1910_121048 crossref_primary_10_1016_j_medcle_2018_01_021 crossref_primary_10_1111_tid_12822 crossref_primary_10_1007_s00520_023_07654_1 |
| Cites_doi | 10.1038/sj.bmt.1704380 10.1053/bbmt.2002.v8.pm12374456 10.1080/01621459.1958.10501452 10.1093/clinids/23.4.795 10.1086/516925 10.1038/bmt.2008.313 10.1016/j.bbmt.2009.04.004 10.1038/sj.leu.2403105 10.1182/blood-2004-02-0545 10.1182/blood-2009-12-234096 10.1111/j.1399-3062.2004.00075.x 10.1016/j.bbmt.2005.09.004 10.1056/NEJM199103073241005 10.1038/sj.bmt.1701246 10.1016/j.bbmt.2009.07.006 10.1097/01.cco.0000357474.66035.9b 10.1097/01.qco.0000172699.90525.80 10.1038/sj.bmt.1701614 10.1038/sj.bmt.1703643 10.1038/bmt.2009.362 10.1038/bmt.2008.10 10.1016/S0301-472X(03)00201-7 10.1080/10245330310001612125 10.1016/j.bbmt.2003.09.006 10.1038/sj.bmt.1703180 10.1038/sj.bmt.1703150 10.1016/j.bbmt.2007.07.007 10.1038/sj.bmt.1703118 10.1016/S1083-8791(03)00100-9 10.1172/JCI107880 |
| ContentType | Journal Article |
| Copyright | 2011 John Wiley & Sons A/S 2011 John Wiley & Sons A/S. |
| Copyright_xml | – notice: 2011 John Wiley & Sons A/S – notice: 2011 John Wiley & Sons A/S. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7T5 7T7 8FD C1K FR3 H94 P64 7X8 |
| DOI | 10.1111/j.1600-0609.2011.01724.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | Technology Research Database CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0609 |
| EndPage | 51 |
| ExternalDocumentID | 22023368 10_1111_j_1600_0609_2011_01724_x EJH1724 ark_67375_WNG_PDTW7RHF_0 |
| Genre | article Clinical Trial Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AAQQT AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AIACR AIAGR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EGARE EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 Y6R YFH YUY ZCG ZGI ZXP ZZTAW ~IA ~WT AAHHS ACCFJ ADZOD AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE WRC WUP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7T5 7T7 8FD C1K FR3 H94 P64 7X8 |
| ID | FETCH-LOGICAL-c5054-e7f94f0b747a1f6b4b7976e38b3a0539757123a0d623cc8ca57a0eab50c80d163 |
| IEDL.DBID | DR2 |
| ISSN | 0902-4441 1600-0609 |
| IngestDate | Thu Sep 04 19:55:33 EDT 2025 Tue Oct 07 09:44:45 EDT 2025 Mon Jul 21 05:57:05 EDT 2025 Wed Oct 01 05:11:27 EDT 2025 Thu Apr 24 23:00:57 EDT 2025 Wed Jan 22 16:16:32 EST 2025 Sun Sep 21 06:26:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2011 John Wiley & Sons A/S. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5054-e7f94f0b747a1f6b4b7976e38b3a0539757123a0d623cc8ca57a0eab50c80d163 |
| Notes | ArticleID:EJH1724 istex:5228D736CDDEB513AF862E26E645989FF3B955DE ark:/67375/WNG-PDTW7RHF-0 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 22023368 |
| PQID | 1020840772 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_911945506 proquest_miscellaneous_1020840772 pubmed_primary_22023368 crossref_citationtrail_10_1111_j_1600_0609_2011_01724_x crossref_primary_10_1111_j_1600_0609_2011_01724_x wiley_primary_10_1111_j_1600_0609_2011_01724_x_EJH1724 istex_primary_ark_67375_WNG_PDTW7RHF_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2012 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: January 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | European journal of haematology |
| PublicationTitleAlternate | Eur J Haematol |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Rinehart JJ, Balcerzak SP, Sogane AL, et al. Effects of corticosteroids on human monocytes function. J Clin Invest 1974;54:1337-43. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805. Van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002;30:303-9. Piñana JL, Valcárcel D, Fernández Avilés F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010;45:119-1456. Sabry W, Le Blanc R, Labbe' AC, et al. Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009;15:919-29. Hori A, Kami M, Kim S-W, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004;10:65-72. Mothy M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168-77. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Bone Marrow Transplant 2007;13:1304-12. Daly A, McAfee S, Colby C, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003;9:373-82. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft- versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56. Bachanova V, Brunstein CG, Burns LJ, et al. Lower infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009;43:237-44. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-52. Ferrara JL, Deeg HJ. Graft versus host disease. N Engl J Med 1991;324:667-74. Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases. Bone Marrow Transplant 1999;23:589-97. Kornblit B, Masmas T, Madsen HO, et al. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant 2008;41:851-9. Martino R, Caballero MD, Canals C, et al. Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation. Bone Marrow Transplant 2001;28:341-7. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8. Brown JM. The influence of the conditions of hematopoietic cell transplantation on infectious complications. Curr Opin Infect Dis 2005;18:346-51. Seggenwiss R, Einsele H. Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-8. Meijer E, Dekker AW, Lokhorst HM, et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004;6:171-1788. Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9. Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK, Liang R. Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998;21:1137-43. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512-20. Busca A, Lovisone E, Aliberti S, et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003;8:303-11. McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004;33:519-29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8. Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15:1422-30. Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:491-5. Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter). Clin Infect Dis 1997;25:346-8. Valcárcel D, Martino R, Piñana JL, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. Curr Opin Oncol 2009;21(Suppl 1):S35-7. 2004; 104 2009; 43 2009; 21 1974; 54 2002; 30 1995; 15 1997; 25 2002; 8 1958; 53 1999; 23 2004; 6 2003; 17 2001; 28 1998; 21 2003; 31 2007; 13 2004; 10 2010; 45 2004; 33 2010; 115 2003; 8 2003; 9 2008; 41 2005; 18 1991; 324 2005; 11 2009; 15 1996; 23 e_1_2_5_26_2 e_1_2_5_27_2 e_1_2_5_24_2 e_1_2_5_25_2 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_20_2 e_1_2_5_21_2 e_1_2_5_28_2 e_1_2_5_29_2 e_1_2_5_14_2 e_1_2_5_13_2 e_1_2_5_9_2 e_1_2_5_8_2 e_1_2_5_15_2 e_1_2_5_7_2 e_1_2_5_10_2 e_1_2_5_6_2 e_1_2_5_5_2 e_1_2_5_12_2 e_1_2_5_31_2 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_32_2 e_1_2_5_3_2 e_1_2_5_2_2 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_19_2 e_1_2_5_30_2 Przepiorka D (e_1_2_5_16_2) 1995; 15 |
| References_xml | – reference: Rinehart JJ, Balcerzak SP, Sogane AL, et al. Effects of corticosteroids on human monocytes function. J Clin Invest 1974;54:1337-43. – reference: Meijer E, Dekker AW, Lokhorst HM, et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 2004;6:171-1788. – reference: Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8. – reference: McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004;33:519-29. – reference: Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter). Clin Infect Dis 1997;25:346-8. – reference: Kornblit B, Masmas T, Madsen HO, et al. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant 2008;41:851-9. – reference: Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81. – reference: Valcárcel D, Martino R, Piñana JL, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. Curr Opin Oncol 2009;21(Suppl 1):S35-7. – reference: Busca A, Lovisone E, Aliberti S, et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003;8:303-11. – reference: Sabry W, Le Blanc R, Labbe' AC, et al. Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009;15:919-29. – reference: Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Bone Marrow Transplant 2007;13:1304-12. – reference: Seggenwiss R, Einsele H. Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010;115:3861-8. – reference: Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15:1422-30. – reference: Ferrara JL, Deeg HJ. Graft versus host disease. N Engl J Med 1991;324:667-74. – reference: Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases. Bone Marrow Transplant 1999;23:589-97. – reference: Brown JM. The influence of the conditions of hematopoietic cell transplantation on infectious complications. Curr Opin Infect Dis 2005;18:346-51. – reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft- versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56. – reference: Mothy M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168-77. – reference: Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8. – reference: Bachanova V, Brunstein CG, Burns LJ, et al. Lower infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant 2009;43:237-44. – reference: Daly A, McAfee S, Colby C, et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003;9:373-82. – reference: Piñana JL, Valcárcel D, Fernández Avilés F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010;45:119-1456. – reference: Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805. – reference: Martino R, Caballero MD, Canals C, et al. Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation. Bone Marrow Transplant 2001;28:341-7. – reference: Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-52. – reference: Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512-20. – reference: Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9. – reference: Hori A, Kami M, Kim S-W, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004;10:65-72. – reference: Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:491-5. – reference: Van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002;30:303-9. – reference: Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK, Liang R. Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998;21:1137-43. – volume: 53 start-page: 457 year: 1958 end-page: 81 article-title: Non‐parametric estimation from incomplete observations publication-title: J Am Stat Assoc – volume: 13 start-page: 1304 year: 2007 end-page: 12 article-title: Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor publication-title: Biol Bone Marrow Transplant – volume: 6 start-page: 171 year: 2004 end-page: 1788 article-title: Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation publication-title: Transpl Infect Dis – volume: 45 start-page: 119 year: 2010 end-page: 1456 article-title: MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced‐intensity conditioning PBSCT from HLA‐identical siblings publication-title: Bone Marrow Transplant – volume: 30 start-page: 303 year: 2002 end-page: 9 article-title: Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence publication-title: Bone Marrow Transplant – volume: 115 start-page: 3861 year: 2010 end-page: 8 article-title: Immune reconstitution alter allogeneic transplantation and expanding options for immunomodulation: an update publication-title: Blood – volume: 43 start-page: 237 year: 2009 end-page: 44 article-title: Lower infections and lower infection‐related mortality following non‐myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma publication-title: Bone Marrow Transplant – volume: 28 start-page: 491 year: 2001 end-page: 5 article-title: Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation publication-title: Bone Marrow Transplant – volume: 11 start-page: 945 year: 2005 end-page: 56 article-title: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐ versus‐host disease: I. Diagnosis and staging working group report publication-title: Biol Blood Marrow Transplant – volume: 25 start-page: 346 year: 1997 end-page: 8 article-title: Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer. Is it justified? (letter) publication-title: Clin Infect Dis – volume: 8 start-page: 303 year: 2003 end-page: 11 article-title: Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation publication-title: Hematology – volume: 23 start-page: 589 year: 1999 end-page: 97 article-title: Early infections in patients undergoing bone marrow or blood stem transplantation: a 7 year single center investigation of 409 cases publication-title: Bone Marrow Transplant – volume: 33 start-page: 519 year: 2004 end-page: 29 article-title: Outbreaks of infectious disease in stem cell transplant units: a silent cause of death for patients and transplant programmes publication-title: Bone Marrow Transplant – volume: 28 start-page: 243 year: 2001 end-page: 9 article-title: Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen publication-title: Bone Marrow Transplant – volume: 31 start-page: 941 year: 2003 end-page: 52 article-title: Immunologic recovery after hematopoietic stem cell transplantation with nonmyeloablative conditioning publication-title: Exp Hematol – volume: 54 start-page: 1337 year: 1974 end-page: 43 article-title: Effects of corticosteroids on human monocytes function publication-title: J Clin Invest – volume: 21 start-page: 1137 year: 1998 end-page: 43 article-title: Unique risk factors for bacteriaemia in allogeneic bone marrow transplant recipients before and after engraftment publication-title: Bone Marrow Transplant – volume: 18 start-page: 346 year: 2005 end-page: 51 article-title: The influence of the conditions of hematopoietic cell transplantation on infectious complications publication-title: Curr Opin Infect Dis – volume: 15 start-page: 1422 year: 2009 end-page: 30 article-title: Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced intensity conditioning allogeneic transplantation for hematologic malignancies publication-title: Biol Blood Marrow Transplant – volume: 17 start-page: 2168 year: 2003 end-page: 77 article-title: Infectious complications following allogeneic HLA‐identical sibling transplantation with antithymocyte globulin‐based reduced intensity preparative regimen publication-title: Leukemia – volume: 15 start-page: 919 year: 2009 end-page: 29 article-title: Graft versus host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA‐matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality publication-title: Biol Blood Marrow Transplant – volume: 8 start-page: 512 year: 2002 end-page: 20 article-title: Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study publication-title: Biol Blood Marrow Transplant – volume: 10 start-page: 65 year: 2004 end-page: 72 article-title: Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced‐intensity stem cell transplantation publication-title: Biol Blood Marrow Transplant – volume: 21 start-page: S35 issue: Suppl 1 year: 2009 end-page: 7 article-title: Allogeneic stem cell transplantation after reduced‐intensity conditioning for acute myeloid leukaemia: impact of chronic graft‐versus‐host disease publication-title: Curr Opin Oncol – volume: 23 start-page: 795 year: 1996 end-page: 805 article-title: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta‐analysis publication-title: Clin Infect Dis – volume: 28 start-page: 341 year: 2001 end-page: 7 article-title: Reduced intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem transplantation publication-title: Bone Marrow Transplant – volume: 15 start-page: 825 year: 1995 end-page: 8 article-title: 1994 consensus conference on acute GVHD grading publication-title: Bone Marrow Transplant – volume: 9 start-page: 373 year: 2003 end-page: 82 article-title: Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA‐identical and mismatched transplants publication-title: Biol Blood Marrow Transplant – volume: 104 start-page: 961 year: 2004 end-page: 8 article-title: Comparing morbidity and mortality of HLA matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities publication-title: Blood – volume: 41 start-page: 851 year: 2008 end-page: 9 article-title: Haematopoietic cell transplantation with non‐myeloablative conditioning in Denmark: disease‐specific outcome, complications and hospitalization requirements of the first 100 transplants publication-title: Bone Marrow Transplant – volume: 324 start-page: 667 year: 1991 end-page: 74 article-title: Graft versus host disease publication-title: N Engl J Med – ident: e_1_2_5_12_2 doi: 10.1038/sj.bmt.1704380 – ident: e_1_2_5_6_2 doi: 10.1053/bbmt.2002.v8.pm12374456 – ident: e_1_2_5_18_2 doi: 10.1080/01621459.1958.10501452 – ident: e_1_2_5_31_2 doi: 10.1093/clinids/23.4.795 – ident: e_1_2_5_32_2 doi: 10.1086/516925 – ident: e_1_2_5_2_2 doi: 10.1038/bmt.2008.313 – ident: e_1_2_5_29_2 doi: 10.1016/j.bbmt.2009.04.004 – ident: e_1_2_5_8_2 doi: 10.1038/sj.leu.2403105 – ident: e_1_2_5_10_2 doi: 10.1182/blood-2004-02-0545 – ident: e_1_2_5_28_2 doi: 10.1182/blood-2009-12-234096 – ident: e_1_2_5_5_2 doi: 10.1111/j.1399-3062.2004.00075.x – ident: e_1_2_5_17_2 doi: 10.1016/j.bbmt.2005.09.004 – ident: e_1_2_5_26_2 doi: 10.1056/NEJM199103073241005 – ident: e_1_2_5_27_2 doi: 10.1038/sj.bmt.1701246 – ident: e_1_2_5_30_2 doi: 10.1016/j.bbmt.2009.07.006 – ident: e_1_2_5_15_2 doi: 10.1097/01.cco.0000357474.66035.9b – ident: e_1_2_5_22_2 doi: 10.1097/01.qco.0000172699.90525.80 – ident: e_1_2_5_11_2 doi: 10.1038/sj.bmt.1701614 – ident: e_1_2_5_13_2 doi: 10.1038/sj.bmt.1703643 – ident: e_1_2_5_14_2 doi: 10.1038/bmt.2009.362 – ident: e_1_2_5_23_2 doi: 10.1038/bmt.2008.10 – ident: e_1_2_5_21_2 doi: 10.1016/S0301-472X(03)00201-7 – ident: e_1_2_5_20_2 doi: 10.1080/10245330310001612125 – volume: 15 start-page: 825 year: 1995 ident: e_1_2_5_16_2 article-title: 1994 consensus conference on acute GVHD grading publication-title: Bone Marrow Transplant – ident: e_1_2_5_3_2 doi: 10.1016/j.bbmt.2003.09.006 – ident: e_1_2_5_9_2 doi: 10.1038/sj.bmt.1703180 – ident: e_1_2_5_4_2 doi: 10.1038/sj.bmt.1703150 – ident: e_1_2_5_24_2 doi: 10.1016/j.bbmt.2007.07.007 – ident: e_1_2_5_19_2 doi: 10.1038/sj.bmt.1703118 – ident: e_1_2_5_7_2 doi: 10.1016/S1083-8791(03)00100-9 – ident: e_1_2_5_25_2 doi: 10.1172/JCI107880 |
| SSID | ssj0002917 |
| Score | 2.0532832 |
| Snippet | Background and objectives: Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not... Background and objectives : Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not... Whether the intensity of the conditioning regimen affects febrile neutropenia (FN) and severe bacterial infections (SBIs) is not well established. We analyzed... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 46 |
| SubjectTerms | Adult allogeneic hematopoietic stem cell transplantation Bacteria Bacterial Infections - epidemiology Bacterial Infections - etiology Busulfan - administration & dosage Busulfan - adverse effects early post-transplant infections febrile neutropenia Female Graft vs Host Disease - epidemiology Graft vs Host Disease - prevention & control Hematopoietic Stem Cell Transplantation Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects intermediate post-transplant infections Male Melphalan - administration & dosage Melphalan - adverse effects Middle Aged Mucositis - epidemiology Mucositis - etiology Mycophenolic Acid - administration & dosage Mycophenolic Acid - adverse effects Mycophenolic Acid - analogs & derivatives Myeloablative Agonists - administration & dosage Myeloablative Agonists - adverse effects Neutropenia - epidemiology Neutropenia - etiology reduced-intensity conditioning Retrospective Studies Risk Factors severe bacterial infections Time Factors Transplantation Conditioning Transplantation, Homologous |
| Title | Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning |
| URI | https://api.istex.fr/ark:/67375/WNG-PDTW7RHF-0/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1600-0609.2011.01724.x https://www.ncbi.nlm.nih.gov/pubmed/22023368 https://www.proquest.com/docview/1020840772 https://www.proquest.com/docview/911945506 |
| Volume | 88 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVEBS databaseName: Academic Search Ultimate - eBooks customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1600-0609 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0002917 issn: 0902-4441 databaseCode: ABDBF dateStart: 20000101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0902-4441 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1600-0609 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002917 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3batwwEBUlgdKXNr27N1QoffPiiyytHkuT7RJIKCEheRO6GdJN7OC1Ie1TP6G_1F_Jl2TG8m7rkkIofTNr67YazZyRRmcIeZcyoXNTprEsXB4zX7jYZNLFuZHMljYD9YCO4t4-nx-x3ZPiZIh_wrswgR9iveGGK6PX17jAtVmOFznHW9E8kQMTJ9hiNkE8mea8964OfjFJZbJPvotRiDEDCDAO6rmxopGl2sQ__fImGDpGtb1Zmj0gi9WAQjTKYtK1ZmK__cH1-H9GvEXuD-iVfgji9pDc8dUjcndvOJ9_TH5ue_DfPa1Leo6h8EiYRHXlqOuCpOGbynctHgFUp5rqxlOAoPRcf6kbinHudMgARAFNU4_0y_SiXrZX33-0PQ_7GYgCLcGThyGMq4JmwMx7qNEECmro6SrWrIJuYDZ02iBVrXdQ3WkI3m-_UlvjuX3YmH5CjmY7hx_n8ZAkIrYA3ljsRSlZmRhwi3RacsOMAITl86nJNSgYKQoBxlknDnCetVOrC6ETr02R2GniAI0-JRtVXfnnhBrv0P0SWkrGkBfHpFy6jEtegCbUPiJiJRDKDgzqmMjjTP3mScEMKZwhhTOk-hlSlxFJ1yUvAovILcq872VuXUA3C4zCE4U63v-kPm8fHouD-UwlEXm7EkoFugEPfHTl624JTWQJOPDgQEWE_uUbMHYSb7bziDwLAr1uMMsA0OV8GhHei-Wtu652duf49OJfC74k9-DnLGx1vSIbbdP51wD-WvOmX9bXhRZOiA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3bbtQwELVQKwEv3CnhaiTEW1a5OPb6EdEuS-muULVV-2b5Fql0m1RpIhWe-AR-iV_hS5hJsgtBRaoQb5ES3-LxzBl7fIaQVzETOjV5HMrMpSHzmQtNIl2YGslsbhNQD-gozuZ8esB2j7KjPh0Q3oXp-CHWG264Mlp9jQscN6SHq5zjtWgeyZ6KE4wxGwGg3GQc3BZESPu_uKQS2abfxTjEkAEIGIb1XFrTwFZt4m-_uAyIDnFta5gmt8lyNaQuHuVk1NRmZL_8wfb4n8Z8h9zqASx900ncXXLNF_fI9Vl_RH-ffN_24MJ7Wub0FKPhkTOJ6sJR13TChm8K39R4ClAca6orTwGF0lP9qawohrrTPgkQBUBNPTIw07PyvP7x9VvdUrEvQRpoDs48jGFYFTQDlt5DjaZjoYaersLNCugGJkSnFbLVegfVHXfx-_Vnaks8uu_2ph-Qg8nO4u007PNEhBbwGwu9yCXLIwOekY5zbpgRALJ8OjapBh0jRSbAPuvIAdSzdmx1JnTktckiO44cANKHZKMoC_-IUOMdemBCS8kYUuOYmEuXcMkzUIbaB0SsJELZnkQdc3ks1W_OFMyQwhlSOEOqnSF1EZB4XfKsIxK5QpnXrdCtC-jqBAPxRKYO5-_Ux-3FodifTlQUkJcrqVSgHvDMRxe-bM6hiSQCHx58qIDQv3wD9k7i5XYekK1OotcNJglgupSPA8Jbubxy19XO7hSfHv9rwRfkxnQx21N77-cfnpCb8EnS7Xw9JRt11fhngAVr87xd4z8BZnNSqQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3batwwEBUlgdCX3i_uVYXSNy9eW5asx9LNdps2SwgJyZvQzZBkYy-ODWmf-gn9pf5Kv6QztndblxRC6ZvB1s0azZyRRmcIeT1mQicmH4cydUnIfOpCE0sXJkYym9sY1AM6irtzPjtkO8fpcZ8OCO_CdPwQ6w03XBmtvsYF7pcuH65yjteieSR7Kk4wxmwEgHKTpTLD-L7J_i8uqVi26XcxDjFkAAKGYT1X1jSwVZv42y-vAqJDXNsapultslgNqYtHORs1tRnZL3-wPf6nMd8ht3oAS992EneX3PDFPbK12x_R3yffJx5ceE_LnJ5jNDxyJlFdOOqaTtjwTeGbGk8BihNNdeUpoFB6rk_LimKoO-2TAFEA1NQjAzNdlhf1j6_f6paKfQHSQHNw5mEMw6qgGbD0Hmo0HQs19HQVblZANzAhOq2QrdY7qO6ki9-vP1Nb4tF9tzf9gBxOtw_ezcI-T0RoAb-x0Itcsjwy4Bnpcc4NMwJAlk8yk2jQMVKkAuyzjhxAPWszq1OhI69NGtkscgBIH5KNoiz8Y0KNd-iBCS0lY0iNY8ZcuphLnoIy1D4gYiURyvYk6pjLY6F-c6ZghhTOkMIZUu0MqcuAjNcllx2RyDXKvGmFbl1AV2cYiCdSdTR_r_YmB0difzZVUUBeraRSgXrAMx9d-LK5gCbiCHx48KECQv_yDdg7iZfbeUAedRK9bjCOAdMlPAsIb-Xy2l1X2zszfHryrwVfkq29yVR9-jD_-JTchC_ibuPrGdmoq8Y_ByhYmxftEv8JnSBSLQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Degree+of+mucositis+and+duration+of+neutropenia+are+the+major+risk+factors+for+early+post-transplant+febrile+neutropenia+and+severe+bacterial+infections+after+reduced-intensity+conditioning&rft.jtitle=European+journal+of+haematology&rft.au=Facchini%2C+Luca&rft.au=Martino%2C+Rodrigo&rft.au=Ferrari%2C+Angela&rft.au=Pinana%2C+Jose+L&rft.date=2012-01-01&rft.issn=0902-4441&rft.eissn=1600-0609&rft.volume=88&rft.issue=1&rft.spage=46&rft.epage=51&rft_id=info:doi/10.1111%2Fj.1600-0609.2011.01724.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0902-4441&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0902-4441&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0902-4441&client=summon |